Actas urologicas espanolas · 2025
Acute toxicity of SBRT in localized prostate cancer: A Spanish multicenter study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romero Zoghbi S E, López Campos F, Sanz-Rosa D, Fernández Ibiza J, Thuissard-Vasallo I J, Andreu-Vázquez C, Laria C, Andreescu Yagüe J, Krumina E, Ocanto A, Mateos M, Glaría L A, García Cuesta J A, Gonsalves D, Fernández C, Esteban D, Begara de la Fuente J, Rivas D, López Ramírez E, Aakki L, González Ferreira J A, Ristori A, Bezares Alarcón A B, Larrea L, García García R, Couñago F
Аннотация
INTRODUCTION: Stereotactic body radiation therapy (SBRT) has emerged as an effective option for the treatment of localized prostate cancer; however, data from real-world clinical practice remain limited.
MATERIAL AND METHODS: Between January 2020 and December 2023, 251 patients with localized prostate cancer treated with SBRT were included in 12 centers in Spain. The treatment volume included prostate ± seminal vesicles, without prophylactic pelvic radiotherapy. A dose of 35-40 Gy was prescribed in 5 fractions, every other day. Acute genitourinary (GU), gastrointestinal (GI) and sexual toxicity was assessed up to 6 months post-treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
RESULTS: A total of 251 patients were classified based on the National Comprehensive Cancer Network (NCCN®) classification. Four percent of patients had very low-risk disease, 26.3% low-risk, and 66.5% intermediate-risk (27.1% favorable intermediate and 39.4% unfavorable intermediate). Additionally, 2.8% were classified as high-risk and 0.4% as very high-risk. The median patient age was 72 years (range: 65-76), and the baseline PSA was 6.7 ng/ml (range: 5.3-8.7). The median SBRT dose was 40 Gy (range: 35-40 Gy). Grade 2 acute GU toxicity occurred in 6.4% of patients, and grade 3 in 0.4%. Grade 2 GI toxicity was observed in 0.8%, with no cases of grade 3 GI toxicity. Regarding sexual toxicity, 11.2% of patients experienced grade 2, and 1.2% grade 3 toxicity.
CONCLUSIONS: Five-fraction SBRT is a feasible and safe treatment with a low incidence of acute toxicity.
MATERIAL AND METHODS: Between January 2020 and December 2023, 251 patients with localized prostate cancer treated with SBRT were included in 12 centers in Spain. The treatment volume included prostate ± seminal vesicles, without prophylactic pelvic radiotherapy. A dose of 35-40 Gy was prescribed in 5 fractions, every other day. Acute genitourinary (GU), gastrointestinal (GI) and sexual toxicity was assessed up to 6 months post-treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
RESULTS: A total of 251 patients were classified based on the National Comprehensive Cancer Network (NCCN®) classification. Four percent of patients had very low-risk disease, 26.3% low-risk, and 66.5% intermediate-risk (27.1% favorable intermediate and 39.4% unfavorable intermediate). Additionally, 2.8% were classified as high-risk and 0.4% as very high-risk. The median patient age was 72 years (range: 65-76), and the baseline PSA was 6.7 ng/ml (range: 5.3-8.7). The median SBRT dose was 40 Gy (range: 35-40 Gy). Grade 2 acute GU toxicity occurred in 6.4% of patients, and grade 3 in 0.4%. Grade 2 GI toxicity was observed in 0.8%, with no cases of grade 3 GI toxicity. Regarding sexual toxicity, 11.2% of patients experienced grade 2, and 1.2% grade 3 toxicity.
CONCLUSIONS: Five-fraction SBRT is a feasible and safe treatment with a low incidence of acute toxicity.